HER2 heterogeneity was defined as HER2-negative regions detected by fluorescence in situ hybridization (FISH) in 10% of cases, or ERBB2 gene amplification detected in more than 5% but fewer than 50% of tumor cells. The gene discussed is ERBB2; the disease is neoplasm.